China Drafts Biotech Export Controls With Licensing Exemption

China is proposing new export controls for biotechnology that would add five biomedical technologies to Beijing’s export-control list, according to Qz. The draft plan also includes an exemption for pharmaceutical licensing deals.

For pharmaceutical and biotech sales professionals, the proposal puts licensing arrangements alongside a broader policy discussion on how biomedical technologies may be handled across borders.

Draft plan targets biomedical technologies

Qz reports that the proposed measures would place five biomedical technologies on China’s export-control list. The plan is still in draft form and has entered a one-month public consultation.

The report identifies the measure as a biotechnology export-control proposal rather than a finalized rule. The consultation creates a formal period for public input on the draft.

Licensing deals are exempted

A central feature of the proposal is its treatment of pharmaceutical licensing deals. Qz reports that those deals would be exempt from the draft export controls.

The distinction is notable for commercial teams following partnerships, licensing discussions, and technology-related transactions in the pharmaceutical and biotechnology sectors. The draft proposal combines new controls for specified biomedical technologies with a stated exemption for pharma licensing arrangements.

What to watch

• The outcome of the one-month public consultation.
• How the five biomedical technologies are defined in the draft framework.
• Whether the licensing exemption remains part of the final policy approach.

Qz’s report highlights an evolving policy proposal with direct relevance to companies involved in biomedical technology and pharmaceutical licensing. Until the consultation and drafting process advance, the measure remains a proposed export-control plan.